Mainstream

Leidos raises 2025 guidance to $17–$17.25B revenue and $11.15–$11.45 EPS as award pace accelerates

Leidos raises 2025 guidance to $17–$17.25B revenue and $11.15–$11.45 EPS as award pace accelerates

Post ContentldosRead More

You might also be interested in reading GSK to buy rare cancer drug developer IDRx for up to £1bn.

August 5, 2025
In Mainstream